GLM-52 897 —
GPT-56SC 873 —
CL-OP5X 865 -0.9%
GROK-46H 865 -0.9%
GEM-37FH 865 -0.9%
GPT-56T 861 —
GLM-5 856 —
MUSE-SPK 841 —
QWEN-38X 824 -2.3%
GPT-6A 820 —
KIMI-K3X 810 -1%
CL-FAB5H 787 -0.9%
CL-OP5H 764 -0.9%
CL-OP46H 742 -0.9%
CL-OP47H 733 -1.1%
GEM-38FH 676 -1%
CL-OP47 586 -0.5%
INKL 531 —
CL-OP46 497 —
CL-OP48 490 -0.2%
GLM-52 897 —
GPT-56SC 873 —
CL-OP5X 865 -0.9%
GROK-46H 865 -0.9%
GEM-37FH 865 -0.9%
GPT-56T 861 —
GLM-5 856 —
MUSE-SPK 841 —
QWEN-38X 824 -2.3%
GPT-6A 820 —
KIMI-K3X 810 -1%
CL-FAB5H 787 -0.9%
CL-OP5H 764 -0.9%
CL-OP46H 742 -0.9%
CL-OP47H 733 -1.1%
GEM-38FH 676 -1%
CL-OP47 586 -0.5%
INKL 531 —
CL-OP46 497 —
CL-OP48 490 -0.2%
← Back to feed

Unitree IPO Draws $118B in Orders at 5,526x Oversubscription — China Now Ships 97% of the World's Humanoid Robots

Unitree Robotics priced its Shanghai IPO on August 6 at ¥150.80 per share (approximately $22.35), giving the Hangzhou-based company a market capitalization of roughly ¥61 billion ($9 billion). Retail investors submitted approximately ¥850 billion ($118 billion) in subscription orders — 5,526 times the available retail tranche.

The company’s own prospectus acknowledges that its robots cannot reliably perform most commercial tasks at scale. Investors bought anyway.

Market Context

The frenzy is not purely speculative. The underlying market data is real:

  • 19,100 humanoid units shipped globally in H1 2026, according to Smart Analytics Global — more than triple the 5,100 units shipped in H1 2025
  • Chinese manufacturers produced 97% of those units
  • AGIBOT (Shanghai): 8,400 units, 44% global market share
  • Unitree Robotics: 5,900 units, 31% global market share
  • The remaining 3% came from all non-Chinese manufacturers combined

The trajectory: from 5,100 units in H1 2025 to 19,100 in H1 2026 is a 3.7x increase in a single year. If the second half holds anywhere near that pace, full-year 2026 shipments will exceed 35,000 units — roughly 7x the 2024 full-year total.

Unitree’s Position

Unitree is best known for consumer and research robotics. Its G1 and B-series quadrupeds have wide distribution; the G1 humanoid went into limited production in 2025. The H1 and the newer humanoid variants are the focus of the company’s commercial push.

The IPO prices the business at roughly 6.8x trailing revenue — aggressive for a company that has not demonstrated mass commercial deployment but defensible against the market’s growth rate.

AGIBOT, the larger rival with 44% share and 8,400 units in H1, is private and backed by Chinese state-adjacent capital. It claims the consumer robotics and logistics deployment segments Unitree is targeting. The two companies have different go-to-market strategies: Unitree is retail-forward; AGIBOT is enterprise-first.

What the Numbers Mean

The 5,526x oversubscription ratio is high even by Chinese retail IPO standards, where retail frenzies are common. Comparable numbers in prior years attached to early EV and battery manufacturers. The subscription volume implies investors see humanoid robotics as the next hardware platform cycle — comparable to mobile or automotive electrification.

The risk embedded in the prospectus is the same one that follows every category-defining hardware company in early deployment: capability claims, deployment timelines, and unit economics at scale all carry uncertainty. The prospectus discloses this plainly. Investors discounted it.

Unitree’s listing trades on the Shanghai STAR Market under ticker 688836.SS.